- GSK
- 06 August 2024 08:23:52
Source: Sharecast
The FTSE 100 pharmaceuticals giant said a jury in an Illinois state court ruled in its favour, finding it not liable for a plaintiff's colorectal cancer.
It said the verdict aligned with the prevailing scientific consensus, which held that there was no consistent or reliable evidence linking the active ingredient ranitidine to an increased risk of cancer.
The company emphasised that the decision was backed by 16 epidemiological studies that had examined the potential health impacts of ranitidine.
GSK reiterated its commitment to vigorously defending itself against the remaining claims related to the Zantac.
The company also noted that the court had previously dismissed the plaintiff's request for punitive damages, further strengthening GSK's position in the legal battle.
At 0804 BST, shares in GSK were up 0.42% at 1,554p.
Reporting by Josh White for Sharecast.com.